Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Citigroup Ups Watson Pharmaceuticals to 'In-Line'

Citigroup upgraded Watson Pharmaceuticals (WPI) to in-line from underperform.

On Wednesday the company posted 44 cents first-quarter earnings per share on 18% higher revenues. Analyst Angela Larson says her upgrade was driven by valuation. She thinks Watson's valuation -- trading in-line with its peers -- is a reasonable reflection of the balance she believes exists between growth concerns (i.e. marketing capabilities, women's health risk) and opportunity for growth (Oxytrol launch, new generics.)

Larson notes her upgrade comes with some trepidation, as Watson's stock has a history of volatility, with mangement having missed guidance and expectations in the past. Still, she raised her $30 target to $34, with shares trading at 16.5 times her $2.04 2004 earnings per share estimate.

blog comments powered by Disqus